Stocklytics Platform
Asset logo for symbol FENC
Fennec Pharmaceuticals
FENC62
$6.36arrow_drop_down2.60%-$0.17
Penny Stock
Asset logo for symbol FENC
FENC62

$6.36

arrow_drop_down2.60%

Performance History

Chart placeholder
Key Stats
Open$6.66
Prev. Close$6.53
EPS0.04
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$173.22M
PE Ratio159.00
LOWHIGH
Day Range6.35
6.71
52 Week Range5.66
11.92
Ratios
P/B Ratio57.38
Revenue$21.64M
Operating M. %54.16%
Earnings$0.00
Earnings Growth %31.10%
EBITDA Margin %-60.11%
ROE %-1,005.59%
EPS0.04

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$948.40
Perf. (24h)
arrow_drop_up1.52%$14.26
Market Cap$841.10B
Price$511.53
Perf. (24h)
arrow_drop_up1.42%$7.17
Market Cap$464.20B
Price$149.88
Perf. (24h)
arrow_drop_up0.12%$0.18
Market Cap$360.27B
Price$127.76
Perf. (24h)
arrow_drop_down0.93%-$1.21
Market Cap$326.65B

About Fennec Pharmaceuticals (FENC)

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Rostislav Raykov
Headquarters
Research Triangle Park
Employees
36
Exchange
NASDAQ
add Fennec Pharmaceuticals  to watchlist

Keep an eye on Fennec Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Fennec Pharmaceuticals 's (FENC) price per share?

The current price per share for Fennec Pharmaceuticals (FENC) is $6.36. The stock has seen a price change of -$0.17 recently, indicating a -2.6% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Fennec Pharmaceuticals (FENC)?

For Fennec Pharmaceuticals (FENC), the 52-week high is $11.92, which is 87.42% from the current price. The 52-week low is $5.66, the current price is 12.37% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Fennec Pharmaceuticals (FENC) a growth stock?

Fennec Pharmaceuticals (FENC) has shown an average price growth of 0.41% over the past three years. It has received a score of 73 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Fennec Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Fennec Pharmaceuticals (FENC) stock price performance year to date (YTD)?

As of the latest data, Fennec Pharmaceuticals (FENC) has a year-to-date price change of -42.81%. Over the past month, the stock has experienced a price change of -12.28%. Over the last three months, the change has been -41.27%. Over the past six months, the figure is -37.59%. Looking at a longer horizon, the five-year price change stands at 53.62%.

help
Is Fennec Pharmaceuticals (FENC) a profitable company?

Fennec Pharmaceuticals (FENC) has a net income of -$16.34M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 94.08% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 54.16% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $21.64M, although specific revenue growth data is currently not available. The gross profit is $20.36M. Operating income is noted at -$13.01M. Furthermore, the EBITDA is $0.

help
What is the market capitalization of Fennec Pharmaceuticals (FENC)?

Fennec Pharmaceuticals (FENC) has a market capitalization of $173.22M. The average daily trading volume is 137.85K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level